跳至主要内容
临床试验/EUCTR2009-016823-74-SE
EUCTR2009-016823-74-SE进行中(未招募)不适用

An open pilot study to assess the effects of pemirolast on C-reactive protein levels in subjects with coronary artery disease.

Cardoz AB0 个研究点目标入组 12 人开始时间: 2009年11月24日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Subjects with coronary artery disease (CAD):
  • a)CAD (diagnosed on the basis of a previous myocardial perfusion study or cardiac catheterisation, or a history of myocardial infarction or coronary angioplasty or coronary artery bypass surgery).
  • b)Male or female subjects aged 40 – 70 years. Body Mass Index between 19 and 29 kg/m2
  • c)Stable statin therapy since one month.
  • d)High sensitivity CRP (hs-CRP) >2.0 and <10.0 mg/L.
  • e)No change in cardiac medications since one month.
  • f)Female subjects have to be non-fertile, i.e. postmenopausal or surgically sterile.
  • g)In the opinion of the Investigator, the subject will be able to comply with the requirements of the protocol.
  • h)Subjects will have given their written informed consent to participate in the study.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects with CAD:
  • a)Acute illness within the last two weeks.
  • b)Pharmacologically treated type 1 or type 2 diabetes mellitus.
  • c) Recent coronary events (within 3 months)
  • d)Clinical heart failure
  • e)Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiac, pulmonary, metabolic, endocrine, haematological, psychological or other major disorder as judged by the Investigator.
  • f)Pregnancy or breast feeding
  • g)Subjects who previously have demonstrated hypersensitivity to the investigational medicinal product.
  • h)Subjects atopic or with history of allergy as judged by the Investigator.
  • i)Subjects who have used any prescribed systemic, except prescribed statin and cardiovascular medications (beta blockers, calcium inhibitors, ACE-inhibitors, diuretics, clopidogrel (Plavix) and low dose trombyl) or topical medication within 14 days before the first dose administration.
  • j)Subjects who have used any OTC systemic or topical medication within 7 days before the first dose administration (with the exception of vitamin/mineral supplements, paracetamol, NSAIDs or nasal decongestants at the discretion of the Investigator).
  • k)Subjects who have participated in a clinical study involving administration of an investigational drug or a marketed drug within the past 3 months.
  • l)Subjects who have donated blood during the last 3 months or plasma the last month.
  • m)Subjects who have had a clinically significant illness within 4 weeks of the start of the study as judged by the Investigator.
  • n)Subjects who are known to have serum hepatitis or who are carriers of the hepatitis B surface antigen (HBsAg), or hepatitis C antibody, or have a positive result to the test for HIV antigens and/or antibodies.
  • o)Heavy smoker and/or excessive use of alcohol, as judged by the Investigator.

研究者

发起方
Cardoz AB

相似试验